We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Name | Symbol | Market | Type |
---|---|---|---|
Kbw Regional Banking Index | DOWI:KRX | Dow Jones Indices | Index |
Price Change | % Change | Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 0 | - |
RNS Number:4036L Keryx Biopharmaceuticals Inc 21 May 2003 The following is a replacement of an announcement that was released this morning 21 May 2003 at 7.00am under RNS reference No. 3555L. The first paragraph of the previous announcement was incorrect as it stated that shares were sold by the trust of Dr Rosenwald's minor children, when it was in fact a sale of 1,000,000 shares by Dr Rosenwald to the trust of his minor children. All other details remain unchanged. Keryx Biopharmaceuticals, Inc ("the Company") The Company was notified on May 20, 2003, that on the 15 May 2003, 1,000,000 shares of common stock held by Lindsay A Rosenwald were sold by him to a trust for the benefit of his minor children. Dr Rosenwald does not act as a trustee of this trust. The sale was effected at the price of $1.36 per share in an off-market transaction. Following this transaction Dr. Rosenwald has a direct interest in 3,015,123 shares and an indirect interest in 2,568,787 shares (inclusive of the 1,000,000 shares sold to the trust) representing 26.8% of the issued share capital of the Company. 20 May 2003 Contact: Mr Bob Trachtenberg General Counsel, Keryx Biopharmaceuticals, Inc. Tel: 00 972 2541 3500 This information is provided by RNS The company news service from the London Stock Exchange END RDSSEEFMFSDSEEI
1 Year Kbw Regional Banking Index Chart |
1 Month Kbw Regional Banking Index Chart |
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions